NCT05379972 - Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

February 24, 2025

Study Completion Date

December 31, 2028

Conditions

Gastric CancerGastroEsophageal Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200mg IV every 3 weeks starting C2D1

DRUG

Olaparib

Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab

RADIATION

Stereotactic Body Radiation Therapy

Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib

Trial Locations (4)

University of Colorado Health, Aurora

UCHealth Highlands Ranch Hospital, Highlands Ranch

UCHealth Memorial Hospital Central, Colorado Springs

UCHealth Memorial Hospital North, Colorado Springs

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Colorado, Denver

OTHER